Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

Stopped early · Phase 3

Conditions studied: Pancreatic Cancer, Thromboembolism

In brief

RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Anticoagulants such as dalteparin may help prevent blood clots in patients being treated with gemcitabine for unresectable or metastatic pancreatic cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of gemcitabine with or without dalteparin in treating patients who have unresectable or metastatic pancreatic cancer.

Key facts

Study ID: NCT00031837
Run by: Gary Morrow
People needed: 400
Starts: 2002-10-01
Expected to finish: 2006-12-01
Last updated by the study team: 2015-10-14

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

MBCCOP - Gulf Coast — Mobile, Alabama, United States
CCOP - Colorado Cancer Research Program, Incorporated — Denver, Colorado, United States
MBCCOP - University of Illinois at Chicago — Chicago, Illinois, United States
CCOP - Central Illinois — Decatur, Illinois, United States
CCOP - Kalamazoo — Kalamazoo, Michigan, United States
CCOP - Kansas City — Kansas City, Missouri, United States
CCOP - Hematology-Oncology Associates of Central New York — East Syracuse, New York, United States
University of Rochester Cancer Center CCOP Research Base — Rochester, New York, United States
CCOP - Southeast Cancer Control Consortium — Goldsboro, North Carolina, United States
CCOP - Columbus — Columbus, Ohio, United States
CCOP - Dayton — Dayton, Ohio, United States
CCOP - Greenville — Greenville, South Carolina, United States
CCOP - Northwest — Tacoma, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.